Skip to content
Screener

Corcept Therapeutics CORT Q3 2025 earnings

Reported November 4, 2025 · After market close

Revenue$207.6MMiss by $47.7M
EPS$0.16Miss by $0.02
Revenue estimate$255.3M
EPS estimate$0.18

Next report

Nov 4, 2026 (in a month)
Revenue estimate$323.9M
EPS estimate$0.81

Financials

Q3 2025

Income statement

See full
Revenue$207.6M+13.7%
Gross profit$203.0M+13.0%
Operating income$10.2M-78.1%
Net income$19.7M-58.3%
EPS (diluted)$0.16-61.0%

Balance sheet

See full
Cash & equivalents$125.1M-8.9%
Total debt$6.4M-6.4%
Total equity$631.9M-1.1%
Total assets$823.6M+5.0%

Cash flow

See full
Operating cash flow$54.5M-26.2%
CapEx--100%
Free cash flow$54.5M-24.5%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$8.76B+81.1%
Enterprise value$8.64B+83.6%
P/E82.5×+48.4×
P/S11.8×+4.1×

Profitability

See full
Gross margin98.2%-0.2pp
Operating margin8.8%-14.0pp
Net margin14.3%-8.2pp
FCF margin21.9%-0.8pp

Returns & leverage

See full
Return on equity16.7%-9.1pp
Debt / equity0×0.0×
Current ratio3.1×-0.6×

FAQ

When did Corcept Therapeutics report Q3 2025 earnings?
Corcept Therapeutics (CORT) reported Q3 2025 earnings on November 4, 2025 after market close.
What were Corcept Therapeutics's Q3 2025 revenue and EPS?
Corcept Therapeutics reported revenue of $207.6M and eps of $0.16 for Q3 2025.
Did Corcept Therapeutics beat estimates in Q3 2025?
Revenue missed the consensus estimate of $255.3M by $47.7M. EPS missed the consensus estimate of $0.18 by $0.02.
How did Corcept Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 13.7% from $182.5M a year earlier and eps declined 61.0% from $0.41.
Where can I find Corcept Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-048814) and the 10-Q periodic report (0001628280-25-048841) directly on SEC EDGAR. The filing index links above go to sec.gov.